Related Experiment Videos
[Malignant hyperthermia--a hereditary and potentially life-threatening condition]
Tonje Haugen1, Mathias Toft, Clemens R Müller
1Department of Public Health, University of North Florida, USA.
Summary
Malignant hyperthermia susceptibility, linked to central core disease, is identified in a Norwegian family due to a novel RYR1 gene mutation. Early identification and dantrolene treatment improve patient outcomes during anesthesia.
Area of Science:
- Anesthesiology
- Genetics
- Neuromuscular Disorders
Background:
- Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder triggered by anesthetics.
- MH susceptibility is inherited in an autosomal dominant pattern and often associated with myopathies.
- Central core disease (CCD) is a congenital myopathy frequently linked to MH susceptibility.
Observation:
- A Norwegian family with CCD and MH susceptibility was studied.
- A novel mutation (c.14558C>T) in the ryanodine receptor gene (RYR1) was identified in affected family members.
- This mutation results in an amino acid substitution (Thr4853Ile) at a conserved residue in the RYR1 protein.
Findings:
- The identified RYR1 mutation is associated with MH susceptibility in this family.
- Genetic analysis provides a molecular basis for MH susceptibility in individuals with CCD.
- Literature review highlights the clinical presentation and genetic underpinnings of MH.
Implications:
- Early identification of MH susceptibility can significantly reduce mortality associated with anesthesia.
- Dantrolene is a crucial treatment for MH episodes.
- Diagnostic tools, including muscle contracture tests and molecular genetic testing, are vital for at-risk individuals and families.